However, inhibition of endonuclease activity of APE1, rather than REDOX function, could interact with NPM1 to trigger p53-mediated effects on colon cancer cell metabolism and improve its sensitivity to targeted drugs [22]. The gene discussed is TP53; the disease is malignant colon neoplasm.